AeproMED | Develops innovative solutions for inhalation medicine

Company Overview

Advancing Drug-Device Integration for Inhalation Therapy

AeproMED is dedicated to advancing inhalation drug development and intelligent respiratory care through a Drug + Device + Data approach. Built around the AIRHYPER™ Platform, we connect drug formulation, medical devices, and treatment data into a seamless Device-Drug Co-Validation workflow.

From aerosol characterization and preclinical validation to smart nebulization and treatment data management, AIRHYPER™ streamlines the entire inhalation development journey—from research to clinical translation.We help pharmaceutical companies, biotechnology firms, CRO/CDMOs, and research institutions accelerate innovation while reducing development complexity.

AIRHYPER™ -1 Stop Inhalation Drug Development Platform

A comprehensive platform integrating inhalation drug development, aerosol characterization, preclinical validation, and drug-device co-development to accelerate innovation from research to clinical translation.

Key Capabilities:
• Drug-Device Co-Development
• Aerosol Characterization
• Lung Deposition Evaluation
• Preclinical Inhalation Research
• Regulatory Support

NEBreath™ Smart Nebulization for Connected Respiratory Care

A next-generation vibrating mesh nebulizer designed for efficient aerosol delivery, improved treatment adherence, and future integration with digital respiratory care.

Key Features:
• High aerosol consistency
• Suspension & high-viscosity compatibility
• Low residual volume
• Portable & rechargeable
• Bluetooth-ready (Future)

AniFree™ Advanced Preclinical Inhalation Research System

A nose-only inhalation exposure system enabling precise and reproducible aerosol delivery for preclinical respiratory research.

Key Features:
• Conscious animal exposure
• Precise aerosol control
• Drug efficacy evaluation
• PK/PD studies
• Translational research